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Background: HbA1c is recommended for monitoring glycaemic control in people with cystic fibrosis-related diabetes (CFRD). However the
relationship between HbA1c and mean plasma glucose concentration (MPG) has not been established in CFRD, as in other forms of diabetes
mellitus.
Methods: 20 people (13 male, 29.7T8.8 years, 10 CFRD) with cystic fibrosis (CF) underwent HbA1c measurement and 48 h continuous
glucose monitoring for estimation of MPG. The relationship between HbA1c and MPG was established and compared to the reported
relationship for type 1 diabetes.
Results: HbA1c was strongly correlated with MPG (R
2=0.888, p <0.0001) in CF. The relationship of MPG to HbA1c was described by
the equation MPG=(1.47HbA1c)1.15, giving a 1.47 mmol L1 change in MPG per 1% change in HbA1c. This equation predicts
that MPG in people with CF and HbA1c <7.0% will be similar to MPG in people with type 1 diabetes who achieve the same HbA1c
target.
Conclusions: These results imply that HbA1c<7.0% will predict good blood glucose control in CF as in type 1 diabetes. However, although
HbA1c predicts complications in type 1 diabetes, further studies are required to establish the relationship between HbA1c and diabetic
complications in people with CFRD.
D 2005 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic fibrosis; HbA1c; Cystic fibrosis-related diabetes1569-1993/$ - see front matter D 2005 European Cystic Fibrosis Society. Publish
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Abbreviations: CF, cystic fibrosis; CFRD, cystic fibrosis related
diabetes; MPG, mean plasma glucose concentration; DCCT, diabetes
control and complications trial; HbA1c, glycosylated haemoglobin; CGMS,
continuous glucose monitoring system.
i This data was presented at a conference of the European Cystic Fibrosis
Society, Birmingham, UK in June 2004 [25].
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Improved clinical care has dramatically increased the life
expectancy of people with cystic fibrosis. As people with
cystic fibrosis live longer, glucose intolerance and cystic
fibrosis-related diabetes (CF-related diabetes) are becoming
more prevalent, affecting 12% of people on the Cystic
Fibrosis Foundation Patient Registry in 2002 [1]. People
with CF-related diabetes are at risk of microvascular
diabetic complications [2–4] and treatment of CF-related
diabetes should aim both to control symptoms of diabetes
and to prevent complications.
The risk of microvascular complications in people with
type 1 and type 2 diabetes mellitus without cystic fibrosis iss 5 (2006) 27 – 31ed by Elsevier B.V. All rights reserved.
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interventions to lower blood glucose reduce these compli-
cations [5,6]. Glycaemic control can be determined by
multiple daily plasma glucose concentration measurements,
but in practice patient adherence to a daily monitoring
regime may be poor. The Diabetes Control and Compli-
cations Trial (DCCT) established that glycosylated haemo-
globin (HbA1c) can be used reliably to estimate mean
plasma glucose concentrations and determine glycaemic
control [7]. Quarterly HbA1c was related to seven-point
capillary daily blood glucose profiles by linear regression
and change in daily mean plasma glucose per 1% increase
in HbA1c was 1.98 mmol L
1 [7]. Use of HbA1c to
monitor glycaemic control is supported by both the DCCT
and UK Prospective Diabetes Study, which showed HbA1c
to be strongly correlated with risk of complications and
reduction in HbA1c to be related to improved outcomes
[5,6]. The American Diabetes Association currently rec-
ommends that patients with diabetes attempt to achieve
HbA1c <7.0% [8].
Several bodies recommend the use of HbA1c for
monitoring glycaemic control in patients with CF-related
diabetes [9,10]. However the relationship between HbA1c
and mean plasma glucose has not been established in CF-
related diabetes as it has in other forms of diabetes
mellitus. HbA1c was elevated in Danish people with cystic
fibrosis and established diabetes (HbA1c 8.6%) compared
to those with cystic fibrosis and normal glucose tolerance
(HbA1c 5.2%) [11], suggesting a role for the assay.
However other investigators have found that HbA1c alone
cannot be used for the diagnosis of diabetes in people with
cystic fibrosis [12]. It is possible that red blood cell
abnormalities described in people with cystic fibrosis, such
as iron deficiency anaemia [13] and shortened red blood
cell life span [14], could influence HbA1c [15] and impair
its usefulness as a measure of glycaemic control in CF-
related diabetes. The aim of our study therefore was to
describe the relationship between mean plasma glucose
and HbA1c in people with cystic fibrosis and determine
whether this was similar to the relationship previously
described for people with type 1 diabetes mellitus without
cystic fibrosis.2. Methods
2.1. Participants
20 people with cystic fibrosis, 10 of whom had CF-
related diabetes, were recruited from the cystic fibrosis
clinic at the Royal Brompton Hospital. The diagnosis of
cystic fibrosis had previously been confirmed on the basis
of a positive sweat test in conjunction with typical
clinical features of cystic fibrosis, with or without
genotype confirmation. The diagnosis of CF-related
diabetes had previously been made on the basis ofelevated random blood glucose with symptoms or
abnormal oral glucose tolerance test. Participants were
excluded if they had been admitted to hospital, had
received home intravenous antibiotics, had had a recent
change in systemic steroid dose or recent commencement
of enteral feeding within 6 weeks of the study, were
pregnant or were medically unfit at the time of the study.
The study was approved by the Local Research Ethics
Committee at the Royal Brompton Hospital and was in
accord with the Declaration of Helsinki. All participants
gave written informed consent for their inclusion in the
study.
2.2. Continuous glucose monitoring
A MiniMed Continuous Glucose Monitoring System
(CGMS) was used to collect glucose readings over a 48 h
period. A glucose sensing electrode was inserted subcuta-
neously through an insertion needle into the subcutaneous
tissue on the anterior abdominal wall using a spring-
loaded device (the Sen-Serter). Glucose oxidase is
covalently bonded onto the sensor surface. It catalyses
the oxidation of glucose present within the interstitial fluid
which generates an electrical current. The current is
carried by a cable to a pager-sized monitor that analyzes
the data every 10 s and reports average values every 5
min. Sensor readings were calibrated by the monitor
against capillary blood glucose measurements obtained by
conventional self-monitoring blood glucose meter (Accu-
Chek Advantage System, Roche Diagnostics LTD).
Patients were asked to enter at least 3 daily self-
monitoring blood glucose measurements. Glucose values
outside the range of 2.2–22.0 mmol L1 were reported as
2.2 or 22.0 mmol L1.
Information from the Minimed CGMS monitor was
downloaded via the Com-Station using MiniMed CGMS
Solutions Software version 3.0A. The mean of all sensor
glucose values for each individual was calculated using
CGMS software and converted to mean plasma glucose
by adding 11% to mean sensor blood glucose values
[16].
2.3. Measurement of glycosylated haemoglobin
Venous samples were taken from each participant on the
first day of monitoring. HbA1c was measured using an ion-
exchange chromatography method, which is DCCT aligned.
The normal range for this method is 4.3–6.1%.
2.4. Statistical analysis
Values are given as meanT standard deviation except
where stated. Linear regression was performed to
determine the relationship between mean plasma glucose
and HbA1c. Statistical analysis was performed using Sta-
tistical Package for Social Science Version 11.5 (SPSS,
Table 1
Calculated mean plasma glucose concentrations at different HbA1c (%) for
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significant.
people with cystic fibrosis and type 1 diabetes mellitus
HbA1c (%) Mean plasma glucose
in people with cystic
fibrosis (mmol L1)
Mean plasma glucose
in people with type 1
diabetes (mmol L1)
5 6.2 5.6
6 7.7 7.6
7 9.2 9.6
8 10.6 11.5
9 12.1 13.5
The relationship between HbA1c and mean plasma glucose for people with
cystic fibrosis was:
Mean plasma glucose mmol L1
  ¼ 1:47 HbA1cð Þ  1:15:
The relationship between HbA1c and mean plasma glucose for people with
type 1 diabetes was:
Mean plasma glucose mmol L1
  ¼ 1:98 HbA1cð Þ  4:29 [7].
These equations were used to calculate mean plasma glucose for a range of
HbA1c values which are compared in the table. People with CF-related
diabetes who achieve the American Diabetes Association HbA1c target of
<7% [8] have similar blood glucose control to people with type 1 diabetes
mellitus.3. Results
3.1. Participants
20 participants (13 male, 7 female) were recruited. Mean
age was 29.7T8.8 years. Of the participants with CF-related
diabetes, 7 people were established on insulin therapy, one
person was taking oral hypoglycaemic medication and 2
participants had recently been diagnosed with diabetes,
commencing treatment after the study.
3.2. Relationship between mean plasma glucose
concentration and HbA1c in participants with cystic fibrosis
Mean plasma glucose was calculated from 577T26
glucose readings recorded for each participant.
The relationship between HbA1c and mean plasma
glucose in participants with CF-related diabetes is shown
in Fig. 1. HbA1c was strongly correlated with mean plasma
glucose (adjusted R2=0.888, p<0.0001). The relationship
of mean plasma glucose concentrations to HbA1c is
described by the equation:
Mean plasma glucose ¼ 1:47 HbA1cð Þ  1:15
i.e. change in mean plasma glucose per HbA1c increase of
1% was 1.47 mmol L1.H
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Fig. 1. Graph demonstrating the relationship between HbA1c and mean 24 h plas
with cystic fibrosis assessed in this study (n =20). The relationship between HbA1c
is shown as a continuous line described by mean plasma glucose (mmol L1)=
glucose, adjusted R2=0.888, p <0.0001. The relationship between HbA1c and mea
Diabetes Control and Complications Trial [7] as mean plasma glucose (mmol L3.3. Comparison of relationship between mean plasma
glucose concentration and HbA1C in people with cystic
fibrosis and those with type 1 diabetes mellitus
The regression line describing the relationship between
HbA1c and mean plasma glucose for study participants with
cystic fibrosis is compared in Fig. 1 to the regression line
previously reported for people with type 1 diabetes mellitusbA1c (%)
1110987
ma glucose concentrations. Filled triangles represent values for individuals
and mean plasma glucose concentration for people with CF-related diabetes
(1.47HbA1c)1.15. HbA1c was strongly correlated with mean plasma
n plasma glucose for people with type 1 diabetes mellitus was defined in the
1)= (1.98HbA1c)4.29 and is drawn as a broken line for comparison.
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estimated for different HbA1c levels from the regression
lines for people with cystic fibrosis and type 1 diabetes
mellitus, respectively. The American Diabetes Association
target HbA1c of <7.0% [8] predicts similar mean plasma
glucose concentrations in the 2 groups.4. Discussion
We have shown that there is a strong correlation between
HbA1c and mean plasma glucose concentrations in people
with CF-related diabetes and that the relationship between
HbA1c and mean plasma glucose is similar, though not
identical, to that seen in people with type 1 diabetes
mellitus. These results imply that HbA1c can be used both to
set targets for and to monitor blood glucose control in
people with CF-related diabetes. The American Diabetes
Association currently recommends that people with diabetes
mellitus attempt to achieve HbA1c <7% [8]. Our study
shows that people with CF-related diabetes and HbA1c <7%
have similar mean plasma glucose concentrations to people
with type 1 diabetes who achieve this target.
The use of HbA1c as a measure of glycaemic control in
cystic fibrosis has important limitations not addressed by
this study. Although HbA1c levels are strongly correlated
with risk of complications in people with type 1 and 2
diabetes [5,6], this relationship has not been formally
quantified for people with CF-related diabetes. Micro-
vascular complications including retinopathy [2–4] and
nephropathy [17] have been described in people with CF-
related diabetes and studies have suggested that these are
more likely in people with cystic fibrosis who have poor
long-term glycaemic control. However it is not yet known
whether targets for glycaemic control set for type 1 and type
2 diabetes will similarly reduce complications in people
with CF-related diabetes.
Our study suggests a role for HbA1c in monitoring blood
glucose control in established CF-related diabetes but does
not add to the debate about the use of HbA1c for the
diagnosis of CF-related diabetes. Some investigators have
used HbA1c to screen for CF-related diabetes [18], although
others have shown that when used alone HbA1c has low
sensitivity for the detection of CF-related diabetes [12].
Yung and colleagues demonstrated that in combination with
random blood glucose and symptoms, HbA1c could be used
successfully to select people with cystic fibrosis who
subsequently had an abnormal oral glucose tolerance test
[19].
In our study we determined the relationship between
HbA1c and mean plasma glucose concentrations in people
with CF-related diabetes who were clinically well. It is not
clear if HbA1c also correlates strongly with mean plasma
glucose if people with cystic fibrosis are unwell due to other
aspects of their disease. HbA1c is formed by the non-
enzymatic glycosylation of the haemoglobin-ß chain withinthe erythrocyte and the rate of formation is determined by
the ambient blood glucose concentration [20]. Changes in
haemoglobin could therefore affect HbA1c levels. In people
with type 1 diabetes mellitus, HbA1c was higher in those
with iron deficiency than in controls and HbA1c decreased
following iron supplementation [21]. Iron deficiency is
common in people with cystic fibrosis [22,23] and could
affect the relationship between HbA1c and mean plasma
glucose in CF-related diabetes. By contrast HbA1c was
reduced in people with reduced red cell survival [24] and
there is weak evidence for shortened red cell survival in
cystic fibrosis [14]. We did not determine the effect of
haematological parameters on HbA1c in our study of CF-
related diabetes and this would be an area for further study.
Interpretation of this study requires consideration of
methods used. There are many types of assay for quanti-
fication of glycosylated haemoglobin. Methods differ in
terms of glycated components measured, factors that
interfere with the assay and non-diabetic Fnormal_ range
[20]. The A1C test has become the preferred standard for
assessing glycaemic control and has been shown to predict
complications of diabetes in the Diabetes Control and
Complications (DCCT) trial [6]. However even results from
this single assay may not be comparable between centres.
Laboratories are now able to standardise A1C assay results
to DCCT values to ensure that HbA1c measured in clinical
practice predicts complications as in clinical trials [20]. In
our study the HbA1c assay used was DCCT-aligned. This
allowed us to compare the relationship between HbA1c and
mean plasma glucose concentrations in people with CF-
related diabetes to the same relationship in people with type
1 diabetes mellitus [7].
We included 20 participants with cystic fibrosis in our
analysis, 10 of whom had CF-related diabetes. As the
relationship between HbA1c and mean plasma glucose is
continuous we felt that people without diabetes could be
included to increase numbers [7]. Our small numbers mean
that our study should be considered to be a pilot, establishing
a new method for assessing the usefulness of HbA1c for
blood glucose monitoring in cystic fibrosis. One limitation of
these small numbers is that few participants with high HbA1c
values were included. This study therefore does not
completely address the question as to whether HbA1c
accurately reflects hyperglycaemia. However our partici-
pants did have a good range of lower HbA1c values, allowing
more accurate prediction of mean plasma glucose when
HbA1c <7%. This is important as the American Diabetes
Association currently recommends that patients with type 1
diabetes attempt to achieve HbA1c <7.0% to minimise the
risk of long-term diabetic complications [8]. Our study
shows that HbA1c <7.0% predicts similar mean plasma
glucose in people with cystic fibrosis as it does in people
with type 1 diabetes (Table 1). This implies that HbA1c <7%
is a reasonable treatment target for CF-related diabetes,
irrespective of the relationship between mean plasma
glucose and HbA1c at higher blood glucose concentrations.
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mean plasma glucose in people with CF-related diabetes and
have demonstrated that people with CF-related diabetes who
achieve HbA1c concentrations <7% have mean plasma
glucose at concentrations demonstrated to be associated with
lower risk of complications in people with type 1 diabetes
mellitus [6]. Further studies are required to confirm these
findings in larger numbers of people with CF-related diabetes
and to determine whether targets for glycaemic control set for
type 1 and type 2 diabetes mellitus will similarly reduce
complications in people with CF-related diabetes.References
[1] Cystic Fibrosis Foundation. Patient Registry Annual Report. Bethesda,
Maryland.
[2] Lanng S, Thorsteinsson B, Lund-Andersen C, Nerup J, Schiotz PO,
Koch C. Diabetes mellitus in Danish cystic fibrosis patients:
prevalence and late diabetic complications. Acta Paediatrica
1994;83:72–7.
[3] Sullivan MM, Denning CR. Diabetic microangiopathy in patients with
cystic fibrosis. Pediatrics 1989;84:642–7.
[4] Yung B, Landers A, Mathalone B, Gyi KM, Hodson ME. Diabetic
retinopathy in adult patients with cystic fibrosis-related diabetes.
Respir Med 1998;92:871–2.
[5] UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-
glucose control with sulphonylureas or insulin compared with
conventional treatment and risk of complications in patients with type
2 diabetes (UKPDS 33). Lancet 1998;352:837–53.
[6] The Diabetes Control and Complications Trial Group. The effect of
intensive treatment of diabetes on the development and progression of
long-term complications in insulin-dependent diabetes mellitus. NEJM
1993;329:977–86.
[7] Rohlfing CL, Wiedmeyer HM, Little RR, England JD, Tennill A,
Goldstein DE. Defining the relationship between plasma glucose and
HbA(1c): analysis of glucose profiles and HbA(1c) in the diabetes
control and complications trial. Diabetes Care 2002;25:275–8.
[8] American Diabetes Association. Standards of medical care for patients
with diabetes mellitus (position statement). Diabetes Care 2001;
24:S33–43.
[9] Management of cystic fibrosis related diabetes. Report of the UK
Cystic Fibrosis Trust Diabetes Working Group. June 2004.[10] Moran A, Hardin D, Rodman D, Allen HF, Beall RJ, Borowitz D, et
al. Diagnosis, screening and management of cystic fibrosis related
diabetes mellitus: a consensus conference report. Diabetes Res Clin
Pract 1999;45:61–73.
[11] Lanng S, Thorsteinsson B, Erichsen G, Nerup J, Koch C. Glucose
tolerance in cystic fibrosis. Arch Dis Child 1991;66:612–6.
[12] Holl RW, Buck C, Babka C, Wolf A, Thon A. HbA1c is not
recommended as a screening test for diabetes in cystic fibrosis. Diabet
Care 2000;23:126.
[13] Ater JL, Herbst JJ, Landaw SA, O’Brien RT. Relative anemia and iron
deficiency in cystic fibrosis. Pediatrics 1983;71:810–4.
[14] Wagener JS, McNeill GC, Taussig LM, Corrigan JJ, Lemen R.
Ferrokinetic and hematologic studies in cystic fibrosis patients. Am J
Pediatr Hematol Oncol 1983;5:153–60.
[15] Stettler C, Mueller B, Diem P. What you always wanted to know about
HbA1c. Schweiz Med Wochenschr 2000;130:993–1005.
[16] Fogh-Andersen N, D’Orazio P. Proposal for standardizing direct-
reading biosensors for blood glucose. Clin Chem 1998;44:655–9.
[17] Brennan AL, Geddes DM, Gyi KM, Baker EH. Clinical importance of
cystic fibrosis-related diabetes. J Cyst Fibrosis 2004;3:209–22.
[18] Hunkert F, Lietz T, Stach B, Kiess W. Potential impact of HbA1c
determination on clinical decision making in patients with cystic
fibrosis-related diabetes. Diabet Care 1999;22:1008–9.
[19] Yung B, Kemp M, Hooper J, Hodson ME. Diagnosis of cystic fibrosis
related diabetes: a selective approach in performing the oral glucose
tolerance test based on a combination of clinical and biochemical
criteria. Thorax 1999;54:40–3.
[20] American Diabetes Association. Tests of glycemia in diabetes. Diabet
Care 2002;25:S97–9.
[21] Tarim O, Kucukerdogan A, Gunay U, Eralp O, Ercan I. Effects of iron
deficiency anemia on haemoglobin A1c in type 1 diabetes mellitus.
Pediatr Int 1999;41:357–62.
[22] Pond MN, Morton AM, Conway SP. Functional iron deficiency in
adults with cystic fibrosis. Respir Med 1996;90:409–13.
[23] Reid DW, Withers NJ, Francis L, Wilson JW, Kotsimbos TC. Iron
deficiency in cystic fibrosis: relationship to lung disease severity
and chronic Pseudomonas aeruginosa infection. Chest 2002;121:
48–54.
[24] Panzer S, Kronik G, Lechner K, Bettelhein P, Neumann E, Dudczak R.
Glycosylated haemoglobins (GHb) an index of red cell survival. Blood
1982;59:1348–50.
[25] Brennan AL, Hodson ME, Geddes DM, Gyi KM, Baker EH.
Describing the relationship between HbA1c and mean plasma glucose
in people with cystic fibrosis. J Cyst Fibros 2004;3:S81.
